JPRN-UMIN000046895已完成未知
Drug-induced lung injury in patients with anti-EGFR antibody and ICI - DILI in patients with anti-EGFR antibody and ICI
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
DLI is seen frequently in patients receiving sequential PD-1 inhibitor and anti-EGFR antibody therapy.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients without CT findings
研究者
相似试验
招募中
3 期
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary FibrosisAcute Exacerbation of Idiopathic Pulmonary FibrosisNCT05674994Fondation Hôpital Saint-Joseph110
Unknown
2 期
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung CancerNSCLCNCT02272127Nanfang Hospital, Southern Medical University100
Unknown
4 期
Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment StudyIdiopathic Pulmonary FibrosisPulmonary HypertensionNonspecific Interstitial PneumoniaInterstitial Lung DiseaseNCT00637065Royal Brompton & Harefield NHS Foundation Trust48
已完成
2 期
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor TherapyEGFR Inhibitor-Induced Skin RashNCT04239846TWi Biotechnology, Inc.74
终止
2 期
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsEGFR-Mutated Non-Small-Cell Lung CarcinomaSmall Cell/NeuroendocrineNCT04538378National Cancer Institute (NCI)4